healthcare-investment-banking
(2)
Shelley Hartman Left Goldman Sachs to Bet on the Cell’s Tiny Messengers
After nineteen years in investment banking, Shelley Hartman traded advice for execution. At Aegle Therapeutics, she is turning an elegant piece of university science into a clinical-stage company, one painstaking milestone at a time.
Filippo Petti
Filippo Petti is the Chief Executive Officer of Leucid Bio, a London-based clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumours built on a proprietary lateral CAR platform spun out of two decades of King's College London research. Appointed CEO in July 2023, Petti pairs a bench-science start at OSI Pharmaceuticals with years on Wall Street as a healthcare investment banker and equity analyst, and a prior run leading Celyad Oncology as CEO and CFO. Under his watch, Leucid moved its lead asset LEU011 into the AERIAL Phase I/IIa trial, reporting early proof-of-concept in relapsed/refractory solid tumours in late 2025.